90Y Ibritumomab Tiuxetan
Abstract
Am J Cancer 2002; 1 (5): 349 GUEST COMMENTARIES 1175-6357/02/0005-0349/$25.00/0 © Adis International Limited. All rights reserved. • with many effective choices available for patients with follic- Y Ibritumomab Tiuxetan A Viewpoint by Ted Wun ular lymphoma, what is the best sequence of therapies? Underly- ing these decisions is the concept that therapy is palliative rather Division of Hematology Oncology, UCDMC, Sacremento, USA than curative; no regimen has yet to result in...